Table 2 Loss of heterozygosity and x-inactivation analysis of synchronous and metachronous urothelial carcinomas
Patient | Samples | Allelic loss of heterozygosity markers | |||
|---|---|---|---|---|---|
D9S171 | D9S177 | D9S303 | TP53 | ||
1. | Normal | NI | NI | NI | NI |
UTT | +/− | +/+ | +/+ | NI | |
Bladder | +/− | +/+ | +/+ | NI | |
2. | Normal | NI | NI | NI | +/+ |
UTT | −/− | NI | −/− | −/− | |
Bladder | +/− | NI | −/− | −/− | |
3. | Normal | NI | NI | NI | +/+ |
UTT | NI | NI | NI | −/− | |
Bladder | NI | NI | NI | −/− | |
4. | Normal | +/+ | +/+ | NI | NI |
UTT | +/− | +/+ | NI | NI | |
Bladder | +/− | +/− | NI | NI | |
5. | Normal | NI | NI | NI | NI |
UTT | NI | NI | NI | NI | |
Bladder | NI | NI | NI | NI | |
6. | Normal | NI | +/+ | +/+ | +/+ |
UTT | +/− | +/+ | +/− | +/− | |
Bladder | +/− | +/+ | +/− | −/− | |